OTCMKTS:VDRM ViaDerma (VDRM) Stock Price, News & Analysis $0.0086 0.00 (0.00%) (As of 12/20/2024 05:55 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartShort Interest About ViaDerma Stock (OTCMKTS:VDRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ViaDerma alerts:Sign Up Key Stats Today's Range$0.0082▼$0.009050-Day Range$0.0047▼$0.012952-Week Range$0.0025▼$0.0150Volume543,559 shsAverage Volume1.72 million shsMarket CapitalizationN/AP/E Ratio0.00Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California.Read More… Receive VDRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViaDerma and its competitors with MarketBeat's FREE daily newsletter. Email Address VDRM Stock News HeadlinesViaDerma Announces Significant 2024 Achievements and International ExpansionDecember 10, 2024 | markets.businessinsider.comViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow GrowthOctober 3, 2024 | finance.yahoo.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 22, 2024 | Crypto Swap Profits (Ad)ViaDerma Completes First Shipment of 500,000 Units to NigeriaSeptember 10, 2024 | stockhouse.comViaDerma Announces Shipment of 500,000 Units of its Flagship Product to NigeriaAugust 14, 2024 | finance.yahoo.comViaDerma Announces Shipment of 500,000 Units of its Flagship Product to NigeriaAugust 13, 2024 | globenewswire.comViaDerma Finalizes Distribution Agreements in Dubai and Announces Six New Key HiresAugust 1, 2024 | globenewswire.comViaDerma Provides Highlights of Quarterly Financial ReportJune 6, 2024 | globenewswire.comSee More Headlines VDRM Stock Analysis - Frequently Asked Questions How have VDRM shares performed this year? ViaDerma's stock was trading at $0.0106 at the beginning of the year. Since then, VDRM stock has decreased by 18.9% and is now trading at $0.0086. View the best growth stocks for 2024 here. How do I buy shares of ViaDerma? Shares of VDRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ViaDerma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ViaDerma investors own include Tesla (TSLA), Dominari (DOMH), Co-Diagnostics (CODX), CEA Industries (CEAD), Organicell Regenerative Medicine (BPSR), Vinco Ventures (BBIG) and AutoZone (AZO). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:VDRM CUSIPN/A CIKN/A Webviadermalicensing.com Phone(310) 734-6111FaxN/AEmployees75Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (OTCMKTS:VDRM) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ViaDerma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ViaDerma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.